Homologation: Why certification determines market success or failure
Before a vehicle or medical device can be launched on the market, it must undergo a critical process: homologation. This certification process confirms that a product meets all safety, environmental, and performance requirements. But how does homologation work in practice—and why do many companies underestimate this step?
The starting point: no market access without approval
The starting point: no market access without approval
Every company that wants to sell vehicles, components, or medical devices internationally faces a key hurdle: homologation. This term describes the process by which products are officially certified as compliant with a country's regulatory standards.
The history of homologation dates back to 1952. At that time, the United Nations Economic Commission for Europe (UNECE) founded the World Forum for Harmonization of Vehicle Regulations (WP.29). This was followed in 1958 by the groundbreaking agreement now known as the “1958 Agreement.” The first signatory states included Italy, the Netherlands, Germany, France, and Hungary.
Today, more than 60 countries are parties to the agreement, including the EU, Japan, Australia, and South Korea. The US, on the other hand, relies on a self-certification system (FMVSS) in which manufacturers themselves confirm compliance.
The challenge: complexity underestimated
- Automotive: ISO 26262 (functional safety), ISO 21434 (cybersecurity), ISO 14001 (environmental management)
- Medical technology: IEC 62304, ISO 13485, CE labeling
The problem: Project teams focus on product development and treat homologation as a downstream step. This can lead to delays, additional costs, and, in the worst case, rejection by the certification body.
The consequences of inadequate homologation: delays and loss of market access
Those who only address homologation requirements shortly before market entry risk significant project delays. Missing documentation, incomplete test reports, or a lack of traceability can result in products not being approved on time.
In highly regulated industries, this means competitive disadvantages, lost sales, and potential damage to reputation. Without valid certification, no product can be legally sold.
The solution: compliance as a competitive advantage
Successful companies integrate homologation into their product development right from the start. This means early analysis of regulatory requirements, systematic documentation, and close cooperation with experienced certification bodies. The homologation process comprises several phases:
- Identification of target markets and regulatory requirements
- Verification of design conformity
- Selection of the certification authority
- Testing in accordance with applicable standards
- Submission of documentation
- Audit and inspection of manufacturing processes
- Granting of approval
This structured approach not only enables market access, but also builds trust among customers and partners.
Conclusion: Proactive rather than reactive
Homologation is not a bureaucratic obstacle, but a strategic success factor. Companies that tackle this process early and systematically shorten their time to market, avoid costly rework, and secure sustainable competitive advantages.
How sepp.med supports you
How sepp.med supports you
Our experienced experts guide you through the entire homologation process for your software solutions: from analyzing regulatory requirements and creating technical documentation to coordinating with certification bodies—tailored to your industry and target markets.
FAQs
Sources
- United Nations Economic Commission for Europe (UNECE): World Forum for Harmonization of Vehicle Regulations (WP.29)
- IGAR: FAQ about UN ECE, WP.29 and harmonization
- ISO 26262: Road vehicles – Functional safety
- Ravizza A, De Maria C, Di Pietro L, Sternini F, Audenino AL and Bignardi C (2019) Comprehensive Review on Current and Future Regulatory Requirements on Wearable Sensors in Preclinical and Clinical Testing. Front. Bioeng. Biotechnol. 7:313. doi: 10.3389/fbioe.2019.00313